WO2023073423 - ERGOLINE-DERIVED AGONISTS OF THE 5-HT2A RECEPTOR
National phase entry:
Publication Number
WO/2023/073423
Publication Date
04.05.2023
International Application No.
PCT/IB2022/000629
International Filing Date
25.10.2022
Title **
[English]
ERGOLINE-DERIVED AGONISTS OF THE 5-HT2A RECEPTOR
[French]
AGONISTES DÉRIVÉS D'ERGOLINE DU RÉCEPTEUR 5-HT2A
Applicants **
DIAMOND THERAPEUTICS INC.
100 King Street West, Suite 6200
Toronto, ON M5X 1B8, CA
Inventors
ISAAC, Methvin
100 King Street West, Suite 6200
Toronto, ON M5X 1B8, CA
Priority Data
63/272,082
26.10.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CIPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1981 | |
| EPO | Filing, Examination | 13458 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 6110 |
Total: 22714 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Provided herein are novel lisuride compounds, processes for their preparation, compositions comprising said compounds, and use in therapy. More particularly, the present disclosure relates to fluorinated and/or deuterated analog useful in the treatment of diseases, disorders or conditions treatable by modulating ther 5-HT2 receptor subtypes.[French]
La présente divulgation concerne de nouveaux composés de lisuride, des procédés pour leur préparation, des compositions comprenant lesdits composés, et leur utilisation en thérapie. Plus particulièrement, la présente divulgation concerne un analogue fluoré et/ou deutéré utile dans le traitement de maladies, de troubles ou d'états pathologiques pouvant être traités par la modulation des sous-types du récepteur 5-HT2.